Cape Town is making groundbreaking progress in medical science with an innovative HIV prevention injection called CABLA, offering two months of protection with just one shot. Although not yet widely accessible, various pilot programs provide access to the CABLA injection, broadening the range of preventative tools available for HIV prevention. This revolutionary development symbolizes a significant step forward in the collective fight against HIV and offers hope for a future without the virus.
South Africa is about to take a significant leap forward in HIV prevention with the upcoming local production of antiHIV injections. The South African branch of Cipla, an Indian pharmaceutical company, is set to manufacture a generic version of the longacting cabotegravir (CABLA) HIV prevention injection at its plants in Benoni and Durban. This development marks a significant step in providing accessible and effective HIV prevention in South Africa. It has the potential to make a substantial impact on HIV infection rates and the overall health of the population.
Deputy Minister of Social Development, Mme Hendrietta BogopaneZulu, has partnered with the United States Agency for International Development (USAID) to launch ChommY, a social and behavioral change program. The program aims to support children aged 10 to 14 years from Ekurhuleni hostels, promote awareness, develop essential life skills, and empower young individuals to make informed choices.
